XM does not provide services to residents of the United States of America.
R
R

Roche

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Roche Holding seen down on plan to halt lung cancer drug trial

BUZZ-Roche Holding seen down on plan to halt lung cancer drug trial ** Shares of Swiss drugmaker Roche Holding ROG.S seen down 2.3% in Julius Baer pre-market trade following its plans to halt trial for lung cancer treatment after 'disappointing' results ** The company said its antibody drug tiragolumab (anti-TIGIT) in combination with its Tecentriq
R
J

Roche to halt trial in latest setback for lung cancer immunotherapy

UPDATE 2-Roche to halt trial in latest setback for lung cancer immunotherapy Rewrites throughout, adds shares in paragraph 4 By Rachel More and Ludwig Burger BERLIN, July 4 (Reuters) - Roche ROG.S will end a lung cancer trial testing its new immunotherapy after the drug did not show a benefit over established treatment Keytruda by Merck & Co MRK.N , casting further doubt on the drug candidate pioneered by the Swiss company.
R
J

Roche to halt trial for lung cancer treatment after 'disappointing' results

Roche to halt trial for lung cancer treatment after 'disappointing' results BERLIN, July 4 (Reuters) - Roche ROG.S intends to halt a trial for combined lung cancer treatment using a new immunotherapy called tiragolumab after results fell short of efficacy targets, the Swiss drugmaker said on Thursday. The trial, dubbed SKYSCRAPER-06, evaluates tiragolumab plus Roche's established drug Tecentriq and chemotherapy.
R

Roche Halts Trial Of Skyscraper-06 Study Due To Reduced Efficacy

BRIEF-Roche Halts Trial Of Skyscraper-06 Study Due To Reduced Efficacy July 4 (Reuters) - ROCHE HOLDING AG ROG.S : ROCHE PROVIDES UPDATE ON PHASE II/III SKYSCRAPER-06 STUDY IN METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER SKYSCRAPER-06 EVALUATING TIRAGOLUMAB PLUS TECENTRIQ AND CHEMOTHERAPY DID NOT MEET PRIMARY ENDPOINTS OF PROGRESSION-FREE SUR
R

Swiss stocks - Factors to watch on July 4

Swiss stocks - Factors to watch on July 4 ZURICH/GDANSK, July 4 (Reuters) - Here are some of the main factors that may affect Swiss stocks on Thursday: UBS AG UBSG.S U.S. bank State Street STT.N has won a mandate to act as custodian bank for a multibillion-dollar compensation fund of the Swiss federal government that was previously at UBS, authorities said on Wednesday.
A
R
U
S

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.